Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 283 entries
Sorted by: Best Match Show Resources per page
The ERA trial: findings and implications for the future.

Climacteric : the journal of the International Menopause Society

Nair GV, Herrington DM.
PMID: 11910581
Climacteric. 2000 Dec;3(4):227-32. doi: 10.1080/13697130008500132.

No abstract available.

Cite
Nair GV, Herrington DM. The ERA trial: findings and implications for the future. Climacteric. 2000;3(4):227-32doi: 10.1080/13697130008500132.
Nair, G. V., & Herrington, D. M. (2000). The ERA trial: findings and implications for the future. Climacteric : the journal of the International Menopause Society, 3(4), 227-32. https://doi.org/10.1080/13697130008500132
Nair, G V, and Herrington, D M. "The ERA trial: findings and implications for the future." Climacteric : the journal of the International Menopause Society vol. 3,4 (2000): 227-32. doi: https://doi.org/10.1080/13697130008500132
Nair GV, Herrington DM. The ERA trial: findings and implications for the future. Climacteric. 2000 Dec;3(4):227-32. doi: 10.1080/13697130008500132. PMID: 11910581.
Copy Download .nbib Format: NLM
C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study.

Circulation

Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, Polak JF, Sutton-Tyrrell K, Herrington DM, Price TR, Cushman M.
PMID: 12821545
Circulation. 2003 Jul 15;108(2):166-70. doi: 10.1161/01.CIR.0000079160.07364.6A. Epub 2003 Jun 23.

BACKGROUND: Increased carotid artery intima-media thickness (IMT) and elevated C-reactive protein (CRP) are both associated with the occurrence of stroke. We investigated whether elevated CRP is a risk factor for ischemic stroke independent of carotid IMT and studied the...

Cite
Cao JJ, Thach C, Manolio TA, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108(2):166-70doi: 10.1161/01.CIR.0000079160.07364.6A.
Cao, J. J., Thach, C., Manolio, T. A., Psaty, B. M., Kuller, L. H., Chaves, P. H., Polak, J. F., Sutton-Tyrrell, K., Herrington, D. M., Price, T. R., & Cushman, M. (2003). C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation, 108(2), 166-70. https://doi.org/10.1161/01.CIR.0000079160.07364.6A
Cao, Jie J, et al. "C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study." Circulation vol. 108,2 (2003): 166-70. doi: https://doi.org/10.1161/01.CIR.0000079160.07364.6A
Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, Polak JF, Sutton-Tyrrell K, Herrington DM, Price TR, Cushman M. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003 Jul 15;108(2):166-70. doi: 10.1161/01.CIR.0000079160.07364.6A. Epub 2003 Jun 23. PMID: 12821545.
Copy Download .nbib Format: NLM
Determination of femoral artery endothelial function by phase contrast magnetic resonance imaging.

The American journal of cardiology

Alexander MR, Kitzman DW, Khaliq S, Darty SN, Hamilton CA, Herrington DM, Link KM, Hundley WG.
PMID: 11704017
Am J Cardiol. 2001 Nov 01;88(9):1070-4. doi: 10.1016/s0002-9149(01)01998-1.

No abstract available.

Cite
Alexander MR, Kitzman DW, Khaliq S, et al. Determination of femoral artery endothelial function by phase contrast magnetic resonance imaging. Am J Cardiol. 2001;88(9):1070-4doi: 10.1016/s0002-9149(01)01998-1.
Alexander, M. R., Kitzman, D. W., Khaliq, S., Darty, S. N., Hamilton, C. A., Herrington, D. M., Link, K. M., & Hundley, W. G. (2001). Determination of femoral artery endothelial function by phase contrast magnetic resonance imaging. The American journal of cardiology, 88(9), 1070-4. https://doi.org/10.1016/s0002-9149(01)01998-1
Alexander, M R, et al. "Determination of femoral artery endothelial function by phase contrast magnetic resonance imaging." The American journal of cardiology vol. 88,9 (2001): 1070-4. doi: https://doi.org/10.1016/s0002-9149(01)01998-1
Alexander MR, Kitzman DW, Khaliq S, Darty SN, Hamilton CA, Herrington DM, Link KM, Hundley WG. Determination of femoral artery endothelial function by phase contrast magnetic resonance imaging. Am J Cardiol. 2001 Nov 01;88(9):1070-4. doi: 10.1016/s0002-9149(01)01998-1. PMID: 11704017.
Copy Download .nbib Format: NLM
The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain?.

Drugs & aging

Wells G, Herrington DM.
PMID: 10641952
Drugs Aging. 1999 Dec;15(6):419-22. doi: 10.2165/00002512-199915060-00001.

The Heart and Estrogen/Progestin Replacement Study (HERS) was the first randomised, double-blind, placebo-controlled study to evaluate the outcome of hormone replacement therapy (HRT) on subsequent cardiac events in postmenopausal women with established coronary heart disease (CHD). Of the 2763...

Cite
Wells G, Herrington DM. The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain?. Drugs Aging. 1999;15(6):419-22doi: 10.2165/00002512-199915060-00001.
Wells, G., & Herrington, D. M. (1999). The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain?. Drugs & aging, 15(6), 419-22. https://doi.org/10.2165/00002512-199915060-00001
Wells, G, and Herrington, D M. "The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain?." Drugs & aging vol. 15,6 (1999): 419-22. doi: https://doi.org/10.2165/00002512-199915060-00001
Wells G, Herrington DM. The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain?. Drugs Aging. 1999 Dec;15(6):419-22. doi: 10.2165/00002512-199915060-00001. PMID: 10641952.
Copy Download .nbib Format: NLM
Dehydroepiandrosterone and cardiac allograft vasculopathy.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

Herrington DM, Nanjee N, Achuff SC, Cameron DE, Dobbs B, Baughman KL.
PMID: 8820087
J Heart Lung Transplant. 1996 Jan;15(1):88-93.

BACKGROUND: Tissue culture, animal model, and epidemiologic studies suggest that dehydroepiandrosterone may inhibit atherosclerosis through its potent antiproliferative effects. Because cardiac allograft vasculopathy is predominantly a proliferative abnormality of intimal and medial smooth muscle cells, plasma levels of dehydroepiandrosterone...

Cite
Herrington DM, Nanjee N, Achuff SC, et al. Dehydroepiandrosterone and cardiac allograft vasculopathy. J Heart Lung Transplant. 1996;15(1):88-93
Herrington, D. M., Nanjee, N., Achuff, S. C., Cameron, D. E., Dobbs, B., & Baughman, K. L. (1996). Dehydroepiandrosterone and cardiac allograft vasculopathy. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 15(1), 88-93.
Herrington, D M, et al. "Dehydroepiandrosterone and cardiac allograft vasculopathy." The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation vol. 15,1 (1996): 88-93.
Herrington DM, Nanjee N, Achuff SC, Cameron DE, Dobbs B, Baughman KL. Dehydroepiandrosterone and cardiac allograft vasculopathy. J Heart Lung Transplant. 1996 Jan;15(1):88-93. PMID: 8820087.
Copy Download .nbib Format: NLM
Visualization and functional assessment of proximal and middle left anterior descending coronary stenoses in humans with magnetic resonance imaging.

Circulation

Hundley WG, Hamilton CA, Clarke GD, Hillis LD, Herrington DM, Lange RA, Applegate RJ, Thomas MS, Payne J, Link KM, Peshock RM.
PMID: 10385498
Circulation. 1999 Jun 29;99(25):3248-54. doi: 10.1161/01.cir.99.25.3248.

BACKGROUND: Coronary artery bypass grafting improves survival in patients with >70% luminal diameter narrowing of the 3 major epicardial coronary arteries, particularly if there is involvement of the proximal portion of the left anterior descending (LAD) coronary artery. Measurement...

Cite
Hundley WG, Hamilton CA, Clarke GD, et al. Visualization and functional assessment of proximal and middle left anterior descending coronary stenoses in humans with magnetic resonance imaging. Circulation. 1999;99(25):3248-54doi: 10.1161/01.cir.99.25.3248.
Hundley, W. G., Hamilton, C. A., Clarke, G. D., Hillis, L. D., Herrington, D. M., Lange, R. A., Applegate, R. J., Thomas, M. S., Payne, J., Link, K. M., & Peshock, R. M. (1999). Visualization and functional assessment of proximal and middle left anterior descending coronary stenoses in humans with magnetic resonance imaging. Circulation, 99(25), 3248-54. https://doi.org/10.1161/01.cir.99.25.3248
Hundley, W G, et al. "Visualization and functional assessment of proximal and middle left anterior descending coronary stenoses in humans with magnetic resonance imaging." Circulation vol. 99,25 (1999): 3248-54. doi: https://doi.org/10.1161/01.cir.99.25.3248
Hundley WG, Hamilton CA, Clarke GD, Hillis LD, Herrington DM, Lange RA, Applegate RJ, Thomas MS, Payne J, Link KM, Peshock RM. Visualization and functional assessment of proximal and middle left anterior descending coronary stenoses in humans with magnetic resonance imaging. Circulation. 1999 Jun 29;99(25):3248-54. doi: 10.1161/01.cir.99.25.3248. PMID: 10385498.
Copy Download .nbib Format: NLM
Cardiovascular trials of estrogen replacement therapy.

Annals of the New York Academy of Sciences

Herrington DM, Klein KP.
PMID: 11795347
Ann N Y Acad Sci. 2001 Dec;949:153-62. doi: 10.1111/j.1749-6632.2001.tb04014.x.

An impressive body of evidence has suggested that estrogen therapy should be helpful to slow the pathogenesis or progression of atherosclerosis. Estrogen's favorable effects on lipids and endothelial function, coupled with extensive observational epidemiology and data from animal models...

Cite
Herrington DM, Klein KP. Cardiovascular trials of estrogen replacement therapy. Ann N Y Acad Sci. 2001;949:153-62doi: 10.1111/j.1749-6632.2001.tb04014.x.
Herrington, D. M., & Klein, K. P. (2001). Cardiovascular trials of estrogen replacement therapy. Annals of the New York Academy of Sciences, 949153-62. https://doi.org/10.1111/j.1749-6632.2001.tb04014.x
Herrington, D M, and Klein, K P. "Cardiovascular trials of estrogen replacement therapy." Annals of the New York Academy of Sciences vol. 949 (2001): 153-62. doi: https://doi.org/10.1111/j.1749-6632.2001.tb04014.x
Herrington DM, Klein KP. Cardiovascular trials of estrogen replacement therapy. Ann N Y Acad Sci. 2001 Dec;949:153-62. doi: 10.1111/j.1749-6632.2001.tb04014.x. PMID: 11795347.
Copy Download .nbib Format: NLM
Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function.

Women's health issues : official publication of the Jacobs Institute of Women's Health

Herrington DM, Klein KP.
PMID: 11275512
Womens Health Issues. 2001 Mar-Apr;11(2):95-102. doi: 10.1016/s1049-3867(01)00075-5.

No abstract available.

Cite
Herrington DM, Klein KP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues. 2001;11(2):95-102doi: 10.1016/s1049-3867(01)00075-5.
Herrington, D. M., & Klein, K. P. (2001). Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Women's health issues : official publication of the Jacobs Institute of Women's Health, 11(2), 95-102. https://doi.org/10.1016/s1049-3867(01)00075-5
Herrington, D M, and Klein, K P. "Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function." Women's health issues : official publication of the Jacobs Institute of Women's Health vol. 11,2 (2001): 95-102. doi: https://doi.org/10.1016/s1049-3867(01)00075-5
Herrington DM, Klein KP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues. 2001 Mar-Apr;11(2):95-102. doi: 10.1016/s1049-3867(01)00075-5. PMID: 11275512.
Copy Download .nbib Format: NLM
beta(2)-Adrenergic receptor polymorphisms and determinants of cardiovascular risk: the Cardiovascular Health Study.

American journal of hypertension

Hindorff LA, Heckbert SR, Psaty BM, Lumley T, Siscovick DS, Herrington DM, Edwards KL, Tracy RP.
PMID: 15797659
Am J Hypertens. 2005 Mar;18(3):392-7. doi: 10.1016/j.amjhyper.2004.10.014.

BACKGROUND: Common Arg16Gly and Gln27Glu polymorphisms of the beta(2)-adrenergic receptor (beta(2)AR) have been associated with hypertension and coronary disease. This analysis of older adults in the Cardiovascular Health Study examined whether these polymorphisms were associated with blood pressure (BP),...

Cite
Hindorff LA, Heckbert SR, Psaty BM, et al. beta(2)-Adrenergic receptor polymorphisms and determinants of cardiovascular risk: the Cardiovascular Health Study. Am J Hypertens. 2005;18(3):392-7doi: 10.1016/j.amjhyper.2004.10.014.
Hindorff, L. A., Heckbert, S. R., Psaty, B. M., Lumley, T., Siscovick, D. S., Herrington, D. M., Edwards, K. L., & Tracy, R. P. (2005). beta(2)-Adrenergic receptor polymorphisms and determinants of cardiovascular risk: the Cardiovascular Health Study. American journal of hypertension, 18(3), 392-7. https://doi.org/10.1016/j.amjhyper.2004.10.014
Hindorff, Lucia A, et al. "beta(2)-Adrenergic receptor polymorphisms and determinants of cardiovascular risk: the Cardiovascular Health Study." American journal of hypertension vol. 18,3 (2005): 392-7. doi: https://doi.org/10.1016/j.amjhyper.2004.10.014
Hindorff LA, Heckbert SR, Psaty BM, Lumley T, Siscovick DS, Herrington DM, Edwards KL, Tracy RP. beta(2)-Adrenergic receptor polymorphisms and determinants of cardiovascular risk: the Cardiovascular Health Study. Am J Hypertens. 2005 Mar;18(3):392-7. doi: 10.1016/j.amjhyper.2004.10.014. PMID: 15797659.
Copy Download .nbib Format: NLM
Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort.

American heart journal

Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB, Herrington DM.
PMID: 16923436
Am Heart J. 2006 Sep;152(3):593-8. doi: 10.1016/j.ahj.2006.02.015.

BACKGROUND: American Heart Association/Centers for Disease Control and Prevention guidelines support the measurement of C-reactive protein (CRP) to further risk stratify individuals at intermediate risk (10%-20% 10-year risk) for heart disease. Determining gender-specific differences in CRP may alter how...

Cite
Lakoski SG, Cushman M, Criqui M, et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006;152(3):593-8doi: 10.1016/j.ahj.2006.02.015.
Lakoski, S. G., Cushman, M., Criqui, M., Rundek, T., Blumenthal, R. S., D'Agostino, R. B., & Herrington, D. M. (2006). Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. American heart journal, 152(3), 593-8. https://doi.org/10.1016/j.ahj.2006.02.015
Lakoski, Susan G, et al. "Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort." American heart journal vol. 152,3 (2006): 593-8. doi: https://doi.org/10.1016/j.ahj.2006.02.015
Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB, Herrington DM. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006 Sep;152(3):593-8. doi: 10.1016/j.ahj.2006.02.015. PMID: 16923436.
Copy Download .nbib Format: NLM
The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study.

American journal of kidney diseases : the official journal of the National Kidney Foundation

Barzilay JI, Peterson D, Cushman M, Heckbert SR, Cao JJ, Blaum C, Tracy RP, Klein R, Herrington DM.
PMID: 15211434
Am J Kidney Dis. 2004 Jul;44(1):25-34. doi: 10.1053/j.ajkd.2004.03.022.

BACKGROUND: Microalbuminuria is a risk factor for coronary heart disease (CHD). It occurs most commonly in the settings of diabetes and hypertension. The mechanisms by which it increases CHD risk are uncertain.METHODS: We examined the cross-sectional association of microalbuminuria...

Cite
Barzilay JI, Peterson D, Cushman M, et al. The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis. 2004;44(1):25-34doi: 10.1053/j.ajkd.2004.03.022.
Barzilay, J. I., Peterson, D., Cushman, M., Heckbert, S. R., Cao, J. J., Blaum, C., Tracy, R. P., Klein, R., & Herrington, D. M. (2004). The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. American journal of kidney diseases : the official journal of the National Kidney Foundation, 44(1), 25-34. https://doi.org/10.1053/j.ajkd.2004.03.022
Barzilay, Joshua I, et al. "The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study." American journal of kidney diseases : the official journal of the National Kidney Foundation vol. 44,1 (2004): 25-34. doi: https://doi.org/10.1053/j.ajkd.2004.03.022
Barzilay JI, Peterson D, Cushman M, Heckbert SR, Cao JJ, Blaum C, Tracy RP, Klein R, Herrington DM. The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis. 2004 Jul;44(1):25-34. doi: 10.1053/j.ajkd.2004.03.022. PMID: 15211434.
Copy Download .nbib Format: NLM
Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial.

American heart journal

Lakoski SG, Brosnihan B, Herrington DM.
PMID: 16290959
Am Heart J. 2005 Nov;150(5):907-11. doi: 10.1016/j.ahj.2004.11.025.

OBJECTIVE: To compare the effects of estrogen and estrogen plus progestin on levels of C-reactive protein (CRP) and interleukin-6 (IL-6), and to examine the relationship between these changes and progression of angiographically defined coronary disease.METHODS: Baseline and follow-up (year...

Cite
Lakoski SG, Brosnihan B, Herrington DM. Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial. Am Heart J. 2005;150(5):907-11doi: 10.1016/j.ahj.2004.11.025.
Lakoski, S. G., Brosnihan, B., & Herrington, D. M. (2005). Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial. American heart journal, 150(5), 907-11. https://doi.org/10.1016/j.ahj.2004.11.025
Lakoski, Susan G, et al. "Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial." American heart journal vol. 150,5 (2005): 907-11. doi: https://doi.org/10.1016/j.ahj.2004.11.025
Lakoski SG, Brosnihan B, Herrington DM. Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial. Am Heart J. 2005 Nov;150(5):907-11. doi: 10.1016/j.ahj.2004.11.025. PMID: 16290959.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 283 entries